CD8+ T-cell clones specific for MART1MelanA or gp100 were administered to 10 stage IV melanoma patients by Yee and colleagues.125 Adoptively transferred T-cell clones persisted in vivo in response to low-dose IL-2 treatment, trafficked to tumor sites, and eliminated antigen-positive tumor cells. Mixed response or stable disease was observed in 8 of 10 patients for up to 21 months.
Selected peptide-specific, tumor-reactive CD8+ T-cell clones derived from tumor-infiltrating lymphocytes were administered intravenously to 12 patients with stage IV melanoma after a nonmyeloablative conditioning regimen, followed by differing doses of IL-2.126 Although no objective responses were seen, the same authors then administered oligoclonal populations of mixed CD4 and CD8 T cells to 13 patients after treatment with the same nonmyeloablative chemotherapy regimen.127 Persistence of the transferred T cells for up to 7 months occurred and was associated with their proliferation in vivo and trafficking to tumor sites. Seven PR or CR were observed, with 3 patients having SD. Autoimmune vitiligo was associated with response. Ten HLA-A2+ patients with tyrosinase-positive melanomas received intravenous infusions of tyrosinase 369 < n.377 peptide-primed CTL on day 1 and 5 days later for four cycles.128 Two patients experienced disease regression, but CTL were undetectable in the circulation within 5 minutes after injection. The T cells concentrated in the liver and the spleen but did not especially target tumor tissues.
Was this article helpful?
Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.